A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral Sclerosis
Latest Information Update: 23 Nov 2023
Price :
$35 *
At a glance
- Drugs RT 001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Retrotope
- 23 Nov 2023 Results published in the European Journal of Neurology.
- 15 Sep 2022 Results published in the Retrotope Media Release
- 15 Sep 2022 Status changed from active, no longer recruiting to completed, according to a Retrotope media release.